INT10261

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1989
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 16
Total Number 16
Disease Relevance 5.55
Pain Relevance 7.40

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
spinal cord 1
brain 1
ear 1
Pd (Mus musculus)
Pain Link Frequency Relevance Heat
Enkephalin 39 100.00 Very High Very High Very High
Analgesic 12 99.88 Very High Very High Very High
Pain 1 99.88 Very High Very High Very High
Spinal cord 1 99.64 Very High Very High Very High
narcan 13 99.08 Very High Very High Very High
MU agonist 2 98.90 Very High Very High Very High
Inflammation 10 98.64 Very High Very High Very High
Antinociceptive 12 98.40 Very High Very High Very High
Physical dependence 8 98.12 Very High Very High Very High
tolerance 10 97.76 Very High Very High Very High
Disease Link Frequency Relevance Heat
Disease 433 100.00 Very High Very High Very High
Pressure And Volume Under Development 7 99.84 Very High Very High Very High
Anxiety Disorder 3 99.22 Very High Very High Very High
INFLAMMATION 10 98.64 Very High Very High Very High
Drug Dependence 8 97.92 Very High Very High Very High
Blister 3 94.32 High High
Aids-related Complex 6 93.44 High High
Body Weight Changes 2 88.12 High High
Weight Loss 4 82.88 Quite High
Stress 6 82.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Development of physical dependence is observed after treatment with opioid agonists, but not after chronic i.c.v. administration of mixed inhibitors of enkephalin-degrading enzymes.
Neg (not) Negative_regulation (inhibitors) of enkephalin-degrading associated with mu agonist, physical dependence and enkephalin
1) Confidence 0.42 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1478261 Disease Relevance 0.30 Pain Relevance 0.53
These results confirm the potential of mixed inhibitors of enkephalin-degrading enzymes as new non-addictive analgesics.
Negative_regulation (inhibitors) of enkephalin-degrading associated with analgesic and enkephalin
2) Confidence 0.42 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1478261 Disease Relevance 0.54 Pain Relevance 1.04
Our results suggest that anxiolytic activity of Selank is associated with inhibition of enkephalin-degrading enzymes.
Negative_regulation (inhibition) of enkephalin-degrading associated with anxiety disorder and enkephalin
3) Confidence 0.36 Published 2002 Journal Bull. Exp. Biol. Med. Section Abstract Doc Link 12432865 Disease Relevance 0.35 Pain Relevance 0.43
The potent analgesic responses elicited by systemic administration of RB101, N-[(R,S)-2-benzyl-3[(S)(2-amino-4-methylthio)butyldithio]-1-oxopro pyl]- 1-oxopropyl]-L-phenylalanine benzyl ester, a prodrug able to inhibit enkephalin-degrading enzymes completely after in vivo bioactivation, has made it possible to investigate the development of antinociceptive tolerance after chronic potentiation of endogenous enkephalins.
Negative_regulation (inhibit) of enkephalin-degrading associated with analgesic, tolerance, enkephalin and antinociceptive
4) Confidence 0.23 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1478260 Disease Relevance 0 Pain Relevance 0.73
Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine.
Negative_regulation (inhibitor) of enkephalin-degrading associated with analgesic, tolerance, enkephalin, antinociceptive and morphine
5) Confidence 0.23 Published 1992 Journal Eur. J. Pharmacol. Section Title Doc Link 1478260 Disease Relevance 0 Pain Relevance 1.08
Since the ODIs of both normally raised mice and 7 days monocular deprivation in PD215 animals were indistinguishable from values obtained in halothane-anaesthetized animals (control: p?
Negative_regulation (deprivation) of PD215 associated with halothane
6) Confidence 0.16 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518841 Disease Relevance 0 Pain Relevance 0.05
The hyperlocomotion induced by 5 mg/kg of RB 101, a mixed inhibitor of enkephalin-degrading enzymes able to cross the blood-brain barrier, was previously shown to be mediated by delta-opioid receptor stimulation.
Negative_regulation (inhibitor) of enkephalin-degrading in brain associated with opioid receptor and enkephalin
7) Confidence 0.11 Published 1995 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 7740050 Disease Relevance 0 Pain Relevance 0.49
Whether spinorphin, an endogenous regulator of enkephalin-degrading enzymes, plays a role in an anti-inflammatory action was examined, using a mouse air-pouch assay as a model of acute inflammation.
Negative_regulation (regulator) of enkephalin-degrading associated with inflammation and enkephalin
8) Confidence 0.08 Published 1998 Journal Life Sci. Section Abstract Doc Link 9585107 Disease Relevance 0.27 Pain Relevance 0.31
Quantitative evaluation of ear-skin sections showed that only following DICLO-PD treatment was there a marked decrease in edema.
Negative_regulation (decrease) of DICLO-PD in ear associated with pressure and volume under development
9) Confidence 0.06 Published 2006 Journal J Appl Toxicol Section Abstract Doc Link 16167317 Disease Relevance 0.70 Pain Relevance 0.18
Curvature sensitivity is reduced in PD
Negative_regulation (reduced) of PD associated with disease
10) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2440419 Disease Relevance 0.54 Pain Relevance 0
Finding that curvature sensitivity is decreased in PD would indicate an impaired mechanism of processing and integrating proprioceptive and tactile information.
Negative_regulation (decreased) of PD associated with disease
11) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2440419 Disease Relevance 0.49 Pain Relevance 0
The result is noteworthy because the curvature sensitivity in absolute terms was reduced in most PD patients

Active exploration cannot overcome the loss in passive motion sensitivity in PD

Negative_regulation (loss) of PD associated with disease
12) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2440419 Disease Relevance 0.55 Pain Relevance 0
MAO-B inhibitors in PD
Negative_regulation (inhibitors) of PD associated with disease
13) Confidence 0.02 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2877525 Disease Relevance 1.03 Pain Relevance 0.45
Novel inhibitors of enkephalin-degrading enzymes.
Negative_regulation (inhibitors) of enkephalin-degrading associated with analgesic and enkephalin
14) Confidence 0.02 Published 1989 Journal J. Enzym. Inhib. Section Title Doc Link 2489237 Disease Relevance 0 Pain Relevance 0.62
Spinorphin (LVVYPWT) has been isolated from the bovine spinal cord as an endogenous inhibitor of enkephalin-degrading enzymes.
Negative_regulation (inhibitor) of enkephalin-degrading in spinal cord associated with enkephalin and spinal cord
15) Confidence 0.02 Published 2001 Journal Jpn. J. Pharmacol. Section Abstract Doc Link 11829145 Disease Relevance 0.30 Pain Relevance 1.06
Rasagiline, a novel MAO B inhibitor for PD therapy
Negative_regulation (inhibitor) of PD associated with disease
16) Confidence 0.00 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386362 Disease Relevance 0.49 Pain Relevance 0.43

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox